Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
暂无分享,去创建一个
Susan M. Chang | K. Aldape | M. Prados | M. Gilbert | M. Mehta | F. Lieberman | P. Wen | L. Deangelis | H. Fine | T. Cloughesy | J. Dancey | K. Lamborn | J. Raizer | A. Norden | A. Lassman | W. Yung | L. Abrey | H. Robins | H. Robins | Andrew B. Lassman | Howard A. Fine | Kathleen R. Lamborn | Lisa M. DeAngelis | Jeffrey J. Raizer | Lauren E. Abrey | Michael D. Prados
[1] Susan M. Chang,et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). , 2009, Neuro-oncology.
[2] P. Wen,et al. Targeted drug therapy for meningiomas. , 2007, Neurosurgical focus.
[3] A. Brandes,et al. 2503 ORAL Erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): results from a randomized phase II trial (EORTC 26034) , 2007 .
[4] A. Brandes,et al. Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034 , 2007 .
[5] A. Brandes,et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) , 2007, British Journal of Cancer.
[6] Susan M. Chang,et al. Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC 01-08) , 2006 .
[7] S. Groshen,et al. Salvage chemotherapy With CPT-11 for recurrent meningioma , 2006, Journal of Neuro-Oncology.
[8] Mahlon D. Johnson,et al. Mitogenic Signal Transduction Pathways in Meningiomas: Novel Targets for Meningioma Chemotherapy? , 2005, Journal of neuropathology and experimental neurology.
[9] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[10] P. Gutin,et al. Diagnosis and Treatment of Atypical and Anaplastic Meningiomas: A Review , 2005, Neurosurgery.
[11] F. S. Pardo,et al. TGF α expression in meningioma — tumor progression and therapeutic response , 1995, Journal of Neuro-Oncology.
[12] V. Stieber,et al. Meningioma: Current treatment options and future directions , 2004, Current treatment options in oncology.
[13] Arie Perry,et al. Molecular pathogenesis of meningiomas , 2004, Journal of Neuro-Oncology.
[14] A. Bergenheim,et al. Epidermal growth factor receptor family (EGFR, ErbB2–4) in gliomas and meningiomas , 2004, Acta Neuropathologica.
[15] S. Groshen,et al. Temozolomide for treatment-resistant recurrent meningioma , 2004, Neurology.
[16] K. Lamszus,et al. Meningioma Pathology, Genetics, and Biology , 2004, Journal of neuropathology and experimental neurology.
[17] H. Newton,et al. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up , 2004, British journal of neurosurgery.
[18] Allan H Friedman,et al. Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Prados,et al. A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Hsu,et al. MIB‐1(Ki‐67) index and transforming growth factor‐alpha (TGFα) immunoreactivity are significant prognostic predictors for meningiomas , 1998, Neuropathology and applied neurobiology.
[21] P. Black,et al. Expression and activation of epidermal growth factor receptors in meningiomas. , 1997, Journal of neurosurgery.
[22] Mahlon D. Johnson,et al. The epidermal growth factor receptor is associated with phospholipase C-γ1 in meningiomas , 1994 .
[23] C. Arteaga,et al. The epidermal growth factor receptor is associated with phospholipase C-gamma 1 in meningiomas. , 1994, Human pathology.
[24] G. Schultz,et al. Detection of epidermal growth factor and transforming growth factor alpha protein in meningiomas and other tumors of the central nervous system in human beings. , 1993, Surgery, gynecology & obstetrics.
[25] M. Gregoriou,et al. Epidermal growth factor receptor expression in 72 meningiomas , 1990, Cancer.
[26] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] P. Kelly,et al. Characterization of the epidermal growth factor receptor in human meningioma. , 1987, Cancer research.